Review Article


, Volume 71, Issue 11, pp 1397-1412

First online:

Management Strategies for Recurrent Platinum-Resistant Ovarian Cancer

  • R. Wendel NaumannAffiliated withCarolinas Medical Center Email author 
  • , Robert L. ColemanAffiliated withMD Anderson Cancer Center, University of Texas

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Although ovarian cancer is often a chemosensitive malignancy, patients who are resistant to platinum-based chemotherapy represent a therapeutic challenge. Currently, the only drugs that are US FDA approved to treat this subset of patients are paclitaxel, pegylated liposomal doxorubicin (PLD) and topotecan. The response rates with these agents is in the 10–15% range and overall survival is around 12 months. Other drugs that have shown some activity in platinum-resistant ovarian cancer include the taxane analogues, oral etoposide, pemetrexed and bevacizumab. Unfortunately, randomized phase III trials of second-line chemotherapy in patients with platinum-resistant ovarian cancer have not shown an advantage over existing therapy with respect to progression-free survival or overall survival. The only trial that has reported a significant progression-free survival advantage over standard therapy is a randomized phase II trial of PLD with or without EC145, a folate-linked vinca alkaloid. Final survival results of this trial are pending.